See more : Empresas Copec S.A. (COPEC.SN) Income Statement Analysis – Financial Results
Complete financial analysis of Codiak BioSciences, Inc. (CDAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codiak BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lookers plc (LKKRF) Income Statement Analysis – Financial Results
- TRaaS On Product Inc. (6696.T) Income Statement Analysis – Financial Results
- Envestnet, Inc. (ENV) Income Statement Analysis – Financial Results
- Shanghai Fudan Microelectronics Group Company Limited (688385.SS) Income Statement Analysis – Financial Results
- Bang & Olufsen a/s (BGOUF) Income Statement Analysis – Financial Results
Codiak BioSciences, Inc. (CDAK)
About Codiak BioSciences, Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 22.94M | 2.92M | 388.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.94M | 2.92M | 388.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 64.86M | 73.98M | 59.50M | 36.54M |
| General & Administrative | 27.63M | 19.85M | 21.04M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.63M | 19.85M | 21.04M | 9.90M |
| Other Expenses | 0.00 | 906.00K | 992.00K | 0.00 |
| Operating Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Cost & Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Interest Income | 22.00K | 253.00K | 1.50M | 1.36M |
| Interest Expense | 2.70M | 1.91M | 300.00K | 0.00 |
| Depreciation & Amortization | 6.42M | 1.16M | 5.26M | 1.73M |
| EBITDA | -61.33M | -89.76M | -74.89M | -42.82M |
| EBITDA Ratio | -267.39% | -3,079.21% | -19,301.03% | 0.00% |
| Operating Income | -69.55M | -90.92M | -80.15M | -46.44M |
| Operating Income Ratio | -303.24% | -3,118.97% | -20,657.73% | 0.00% |
| Total Other Income/Expenses | 32.39M | -747.00K | 2.19M | 1.90M |
| Income Before Tax | -37.16M | -91.67M | -77.96M | -44.54M |
| Income Before Tax Ratio | -162.01% | -3,144.60% | -20,092.78% | 0.00% |
| Income Tax Expense | 4.48M | -2.73M | 1.29M | 1.90M |
| Net Income | -41.63M | -88.93M | -79.25M | -44.54M |
| Net Income Ratio | -181.53% | -3,050.81% | -20,425.77% | 0.00% |
| EPS | -1.91 | -14.04 | -6.03 | -3.40 |
| EPS Diluted | -1.91 | -14.04 | -6.03 | -3.40 |
| Weighted Avg Shares Out | 21.79M | 6.33M | 13.13M | 13.11M |
| Weighted Avg Shares Out (Dil) | 21.79M | 6.33M | 13.13M | 13.11M |
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences files for bankruptcy, looks to sell off assets
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports